Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study

NCT06906081 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Cardiovascular Autonomic Neuropathy
Type 2 Diabetes
Diabetic Neuropathies

Interventions

DRUG: Kerendia (Finerenone, BAY94-8862)
DRUG: Placebo

Sponsor

Peter Rossing

Collaborators

[object Object]
[object Object]